secwatch.observer — SEC 8-K summary
======================================

Issuer:     10x Genomics, Inc. (TXG)
CIK:        0001770787
Form:       8-K
Filed at:   2021-08-04T23:59:59+00:00
Accession:  0001770787-21-000041
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

10x Genomics Q2 revenue $115.8M (+170% YoY); settles Bio-Rad litigation
-----------------------------------------------------------------------

- Revenue $115.8M, up 170% YoY and 9% QoQ; net loss narrowed to $11.1M from $40.2M.
- Gross margin 96% aided by $14.7M one-time royalty reversal from Bio-Rad settlement.
- Launched Chromium X platform and began shipping Visium Spatial Gene Expression for FFPE.
- Global settlement with Bio-Rad resolves all outstanding litigation; cross-license agreement.
- Maintains FY2021 revenue guidance $480M-$500M, representing 61%-67% growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1770787/000177078721000041/0001770787-21-000041-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1770787/000177078721000041/txg-20210804.htm
  HTML page:      https://secwatch.observer/filing/0001770787-21-000041

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer